Lipocine: It's All About Tlando, NASH & Patent Trial

Lipocine Inc.'s (LPCN) TLANDO, an oral testosterone product candidate, is back at the FDA altar again, with a decision date now set for August 28, 2020.

from RTT - Biotech https://ift.tt/3cv1P2p
via IFTTT